-
Maximized Efficiency
ALiCE® is extremely efficient, even for complex multimers or membrane proteins - a wide variety of previously impossible targets are in reach within only 24 hours
-
Fully Scalable
ALiCE® is the only eukaryotic cell-free system that scales reliably and seamlessly from early research to large-scale production - designed for the full drug development process
-
Simple yet Flexible
ALiCE® is user-friendly and an open-system from start to finish, with no need for lengthy optimization – removing protein expression as your bottleneck
ALiCE® for Research
Explore small-scale protein expression
ALiCE® for Scale-Up
Advance protein production in large quantities
ALiCE® for HTPE
Accelerate antibody screening with seamless integration
ALiCE® as a Service
An end-to-end solution for novel proteins
Trusted by
Plant-Based ALiCE® Technology Could Shave Weeks Off Vaccine Production
LenioBio has received CEPI (Coalition for Epidemic Preparedness Innovations) funding of up to US $2 million to provide preclinical proof-of-concept that their commercially available, plant-based, and cell-free technology can produce proteins for use in clinical trials testing vaccines against epidemic and pandemic threats in 20-40 days.
mAIbe and LenioBio Announce a New Strategic Collaboration Aimed at Accelerating the Discovery and Experimental Validation of Next-generation Monoclonal Antibodies
By combining mAIbe’s AI-driven platform for antibody design and optimization with LenioBio’s cell-free expression technology, this partnership brings together two complementary strengths to significantly enhance the design–build–test cycle.
Our Purpose: To Make Life-Saving Medicines Accessible to All
We believe that everyone deserves an equal chance to lead a healthy life.
That’s why we created ALiCE®, a disruptive cell-free protein technology that will change the way proteins are produced. Our goal? To simplify biomanufacturing and speed up the delivery of drugs to the patient.
A Therapeutic Target Like No Other
With unmatched therapeutic potential, GPCRs account for ~35% of FDA-approved drugs, achieving the status of the most common class of therapeutic target. They also happen to be one of the most challenging classes of protein to express. In this case study, we explore the rapid expression and in-lysate functional analysis of the CB2 GPCR using the ALiCE® expression system.
ALiCE® Unlocks Access To Novel Cancer Target
Receptor tyrosine kinases (RTKs) are promising cancer targets but are notoriously difficult to express. In a recent Nature Scientific Reports article, researchers at Leeds University combined the ALiCE® cell-free protein expression system with copolymer encapsulation to achieve high-yield production of a key oncogenic RTK membrane target.
